Due to current legislation, Medicare Part D or C plans may only cover Zepbound for obstructive sleep apnea. However, the Centers for Medicare & Medicaid Services may expand weight loss medication ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their GLP-1 products. Lilly markets its dual GIP and GLP-1 receptor agonist, ...

"I've said this before, but as more data comes in I become more convinced that we may look back on these drugs as the ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

Today CMS announced that payments to Medicare Advantage and Part D Prescription Plans would increase by 5.06% next year ...

India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to ...

As the obesity rate among people with type 1 diabetes rises, patients are taking popular weight loss drugs like Ozempic—and ...

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

Long considered resistant to economic downturns, the pharmaceutical industry may face a greater challenge this time around as ...